BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: BioCryst is a biopharmaceutical company engaged in the research and development of drug candidates, primarily focusing on enzyme targets for oncology and infectious diseases. The company has no product sales and relies on license fees, milestone payments, research and development fees, and interest income for revenue. Key drug candidates include Fodosine (BCX-1777) for oncology and peramivir for influenza.

Key Financial Metrics

Liquidity: As of September 30, 2006, the company held approximately $61.6 million in cash, cash equivalents, and marketable securities. Management believes these funds are sufficient to fund operations for at least the next twelve months.

Material Changes vs. Prior Period

• Revenue Growth: Collaborative and other R&D revenues increased significantly to $1.79 million for the quarter (from $32,000 in Q3 2005) and $4.12 million for the nine-month period (from $131,000 in 2005). This is primarily due to the recognition of revenue from the Mundipharma collaboration regarding Fodosine.
• Expense Increases:
  • R&D Expenses: Increased 132.4% for the quarter and 103.9% for the nine months compared to the prior year periods. Drivers include clinical development and manufacturing validation for Fodosine and peramivir, as well as the adoption of FAS 123R (stock-based compensation).
  • G&A Expenses: Increased 87.5% for the quarter and 101.9% for the nine months, largely due to stock-based compensation ($560,000 in Q3; $1.22 million for nine months) and increased personnel costs.
• Net Loss: Net loss widened to $15.6 million for the quarter and $33.6 million for the nine months, compared to $7.6 million and $18.9 million in the respective prior year periods.
• Stock-Based Compensation: The company adopted FAS 123R effective January 1, 2006, resulting in the recognition of $2.24 million in stock-based compensation expense for the first nine months of 2006, whereas no such expense was recognized for employees in the prior year.

Guidance, Outlook, and Risks

Outlook and Cash Burn:

• The average monthly cash burn from normal operations in Q3 2006 was approximately $4.4 million.
• Management estimates the monthly cash burn rate will increase by approximately $1 million due to Phase II peramivir clinical trials planned for the 2006-2007 influenza season.
• The company expects to achieve a milestone with Mundipharma in 2006 or early 2007 and anticipates receiving approximately $3.1 million in receivables from Mundipharma for clinical development costs early in 2007.

Key Developments:

• Fodosine: Received a Special Protocol Assessment (SPA) letter from the FDA for a pivotal Phase IIb trial in T-cell leukemia, expected to initiate later in 2006.
• Peramivir: Submitted a proposal to the Department of Health and Human Services (HHS) for potential funding under a Request for Proposal (RFP) for antiviral drugs. Phase II trials are planned for the 2006-2007 flu season.

Risks and Contingencies:

• Capital Requirements: The company expects to incur substantial losses and will likely need to raise additional capital to complete development and commercialization. Insufficient funds could force delays or elimination of programs.
• Collaboration Dependence: Future revenues depend heavily on the success of collaborations with Roche, Mundipharma, and Green Cross, including the achievement of milestones and regulatory approvals.
• Regulatory Risk: Receipt of an SPA letter does not ensure FDA approval. Clinical trial results may be negative or inconclusive.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $61.6 million cash balance against the projected increased burn rate of ~$5.4 million/month due to new clinical trials.
• Collaboration Milestones: Monitor the timing and achievement of the Mundipharma milestone expected in late 2006 or early 2007, which could provide additional funding.
• HHS Funding: Track the status of the HHS RFP proposal for peramivir funding, which could offset projected cash burn.
• Clinical Trial Initiation: Confirm the start dates and patient enrollment progress for the pivotal Fodosine trial and Phase II peramivir trials.
• Stock-Based Compensation: Review the impact of FAS 123R adoption on future expense recognition, noting $9.75 million of unrecognized compensation cost remaining.